Literature DB >> 31451983

A Matter of TACEte: Plain Vanilla or Combination?

David E Kaplan1,2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31451983      PMCID： PMC7044038          DOI： 10.1007/s10620-019-05793-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy.

Authors:  Wooil Kim; Sung Ki Cho; Sung Wook Shin; Dongho Hyun; Min Woo Lee; Hyunchul Rhim
Journal:  Abdom Radiol (NY)       Date:  2019-06

2.  Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.

Authors:  Marina Serper; Tamar H Taddei; Rajni Mehta; Kathryn D'Addeo; Feng Dai; Ayse Aytaman; Michelle Baytarian; Rena Fox; Kristel Hunt; David S Goldberg; Adriana Valderrama; David E Kaplan
Journal:  Gastroenterology       Date:  2017-03-07       Impact factor: 22.682

3.  Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.

Authors:  Qingfeng Song; Weizheng Ren; Liwei Fan; Meiqi Zhao; Lisha Mao; Shichai Jiang; Chang Zhao; Ying Cui
Journal:  Dig Dis Sci       Date:  2019-07-17       Impact factor: 3.199

4.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

Review 5.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

6.  Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.

Authors:  Zhen-Wei Peng; Yao-Jun Zhang; Min-Shan Chen; Li Xu; Hui-Hong Liang; Xiao-Jun Lin; Rong-Ping Guo; Ya-Qi Zhang; Wan Yee Lau
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

7.  Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma.

Authors:  Chunping Wang; Huaming Wang; Wuwei Yang; Kaiwen Hu; Hui Xie; Ke-Qin Hu; Wenlin Bai; Zheng Dong; Yinying Lu; Zhen Zeng; Min Lou; Hong Wang; Xudong Gao; Xiujuan Chang; Linjing An; Jianhui Qu; Jin Li; Yongping Yang
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

8.  Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Authors:  Bao-Quan Cheng; Chong-Qi Jia; Chun-Tao Liu; Wei Fan; Qing-Liang Wang; Zong-Li Zhang; Cui-Hua Yi
Journal:  JAMA       Date:  2008-04-09       Impact factor: 56.272

9.  Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation.

Authors:  Maria M Rubinstein; Andreas Kaubisch; Milan Kinkhabwala; John Reinus; Qiang Liu; Jennifer W Chuy
Journal:  J Gastrointest Oncol       Date:  2017-12

10.  Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Authors:  Jordi Bruix; Maria Reig; Bruno Sangro
Journal:  J Hepatol       Date:  2017-03-09       Impact factor: 25.083
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.